The current P/E ratio of ILMN cannot be calculated, as the latest EPS of -$8.15 is negative. The last PE ratio of Illumina, recorded in April 2022, was 79.28.
The PE ratio of Illumina has averaged 60.35 over the last ten years. Analyzing the last ten years, ILMN's PE ratio reached its highest point in the Jul 2021 quarter at 90.25, when the price was $474.73 and the EPS was $5.26. The lowest point was recorded in the Apr 2017 quarter, when it reached 34.06 with a price of $170.64 and an EPS of $5.01.
Maximum annual increase: 69.28% in 2021
Maximum annual decrease: -34.67% in 2014
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2023 | N/A | N/A |
| 2022 | 75.04 | -9.14% |
| 2021 | 82.59 | 69.28% |
| 2019 | 48.79 | -7.89% |
| 2018 | 52.97 | 20.25% |
| 2017 | 44.05 | 6.3% |
| 2017 | 41.44 | -31.13% |
| 2016 | 60.17 | -16.56% |
| 2014 | 72.11 | -34.67% |
| Stock name | PE ratio | Market cap |
|---|---|---|
| DGX Quest Diagnostics Inc | 19.41 | $16.21B |
| A Agilent Technologies Inc | 32.31 | $40.06B |
| TMO Thermo Fisher Scientific Inc | 38.79 | $231.76B |
| DHR Danaher Corp | 48.14 | $197.82B |
| PACB Pacific Biosciences Of California Inc | N/A | $581.48M |
| TBIO Telesis Bio Inc | N/A | $6.9M |
| ILMN Illumina Inc | N/A | $19.18B |
The current price to earnings ratio of ILMN cannot be determined, as its EPS of -$8.15 is negative.
The 5-year average PE ratio for ILMN stock is 69.35.
Over the last ten years, the quarterly PE ratio reached its highest level at 90.25 in the Jul 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.